Fernand Labrie

Publications

Page 6 of 26, showing 50 records out of 1263 total, starting on record 251, ending on 300

Publication Category Year
3664. Gyomorey, S., Gupta, S., Lye, S.J., Gibb, W., Labrie, F., Challis, J.R.G. (2000) Temporal expression of prostaglandin H synthase type 2 (PGHS-2) and P450c17 in ovine placentomes with the natural onset of labour. Placenta, 21: 478-486. All publications 2000
408. Labrie, C., Labrie, F., Bélanger, A., Simard, J., Luo, S., Martel, C. (2000) EM-652 (SCH 57068), a third generation SERM (selective estrogen receptor modulator), acting as pure antiestrogen in the mammary gland and endometrium, in: Coutinho, E.M. et Spinola, P., eds: Current Knowledge in Reproductive Medicine. Proceedings of the 10th World Congress on Human Reproduction, Salvador, Brazil, 4-8th May 1999, Elsevier Science B.V., pp 381-397. All publications 2000
3667. Labrie, F. (2000) Maximum androgen blockade in advanced prostate cancer: an overview of the randomised trials. Prostate Cancer trialists' Collaborative Group. Lancet, 355: 1491-8. All publications 2000
48. Labrie, F. (2000) Prostate cancer and combined androgen blockade at all stages of disease, in: Khayat, D. et Hortobagyi, G.N., eds: Progress in Anti-Cancer Chemotherapy, France, Springer, pp 171-187. All publications 2000
791. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (2000) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: (DHEA): Biochemical Physiological and Clinical Aspects, pp 191-213. All publications 2000
49. Labrie, F., Candas, B. (2000) Androgen blockade in prostate cancer [Letter-to-the-Editor]. Lancet, 356: 341-342. All publications 2000
409. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Luu-The, V., Candas, B. (2000) Mechanisms of action of estrogens and antiestrogens, in: Aso, T., Yanaihara, T. et Fujimoto, S., eds: The Menopause at the Millenium: Proceedings of the 9th World Congress on the Menopause, October 17-21, 1999, Yokohama, Japan, Parthenon Publishing, pp 14-22. All publications 2000
359. Labrie, F., Luu-The, V., Labrie, C., Pelletier, G., El Alfy, M. (2000) Intracrinology and the skin. Horm. Res., 54: 218-229. All publications 2000
50. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C. (2000) Role of 17beta-hydroxysteroid dehydrogenases in sex steroid formation in peripheral intracrine tissues. Trends Endocrinol. Metab., 11: 421-427. All publications 2000
51. Labrie, F., Luu-The, V., Lin, S.-X., Simard, J., Labrie, C., El-Alfy, M., Pelletier, G., Bélanger, A. (2000) Intracrinology: role of the family of 17beta-hydroxysteroid dehydrogenases in human physiology and disease. J. Mol. Endocrinol., 25: 1-16. All publications 2000
411. Martel, C., Picard, S., Richard, V., Bélanger, A., Labrie, C., Labrie, F. (2000) Prevention of bone loss by EM-800 and raloxifene in the ovariectomized rat. J. Steroid Biochem. Mol. Biol., 74: 45-56. All publications 2000
608. Mauriège, P., Langin, D., Montminy, V., Martel, C., Després, J.P., Bélanger, A., Labrie, F., Deshaies, Y. (2000) Effect of a long-term percutaneous adrenal steroid treatment on rat adipose tissue metabolism. Int. J. Obes. Relat. Metab. Disord., 24: S148-S150. All publications 2000
52. Pelletier, G., Labrie, C., Labrie, F. (2000) Localization of oestrogen receptor alpha oestrogen receptor beta and androgen receptors in the rat reproductive organs. J. Endocrinol., 165: 359-370. All publications 2000
412. Picard, F., Deshaies, Y., Lalonde, J., Samson, P., Labrie, C., Bélanger, A., Labrie, F., Richard, D. (2000) Effects of the estrogen antagonist EM-652.HCl on energy balance and lipid metabolism in ovariectomized rats. Int. J. Obes. Relat. Metab. Disord., 24: 830-840. All publications 2000
53. Prostate Cancer Triallist’ Collaborative Group; (2000) Maximum androgen blockade in advanced prostate cancer: an overvierw of the randomised trials. Lancet, 355: 1491-1498. All publications 2000
801. Sam, K.-M., Labrie, F., Poirier, D. (2000) N-Butyl-N-methyl-11-(3'-hydroxy-21', 17'-carbolactone-19'-nor-17'alpha-pregna-1',3', 5'(10')-trien-7'alpha-yl)-undecanamide: an inhibitor of type 2 17beta-hydroxysteroid dehydrogenase that does not have oestrogenic or androgenic activity. Eur. J. Med. Chem., 35: 217-225. All publications 2000
54. Singh, R., Eeles, R.A., Durocher, F., Simard, J., Edwards, S., Badzioch, M., Kote-Jarai, Z., Teare, D., Fortd, D., Dearnaley, D., Ardern-Jones, A., Murkin, A., Dowe, A., Shearer, R., Kelly, J., Labrie, F., Easton, D., Narod, S.A., Tonin, P.N., Foulkes, W.D. (2000) High risk genes predisposing to prostate cancer development-do they exist? Prostate Cancer Prostatic Dis., 3: 241-247. All publications 2000
802. Singh, S.M., Gauthier, S., Labrie, F. (2000) Androgen receptor antagonists (antiandrogens): structure-activity relationships. Curr. Med. Chem., 7: 211-247. All publications 2000
360. Sourla, A., Richard, V., Labrie, F., Labrie, C. (2000) Exclusive androgenic effect of dehydroepiandrosterone in sebaceous glands of rat skin. J. Endocrinol., 166: 455-462. All publications 2000
3685. Tatchum-Talom, R., Martel, C., Labrie, C., Labrie, F., Marette, A. (2000) Gender differences in hemodynamic responses to endothelin-1. J. Cardiovasc. Pharmacol, 36: S102-S104. All publications 2000
414. The BRCA1 Exon 13 Duplication Screening Group. (2000) The exon 13 duplication in the BRCA1 gene is a founder mutation present in geographically diverse populations. The BRCA1 Exon 13 Duplication Screening Group. Am J Hum Genet., 67: 207-212. All publications 2000
55. Xu, J., The International Consortium for Prostate Cancer Genetics. (2000) Combined Analysis of Hereditary Prostate Cancer Linkage to 1q24-25: Results from 772 Hereditary Prostate Cancer Families from the International Consortium for Prostate Cancer Genetics. Am J Hum Genet., 66: 945-57. All publications 2000
56. Boivin, R.P., Poirier, D., Labrie, F. (1999) 17alpha-alkan (or alkyn) amide derivatives of estradiol as inhibitors of steroid-sulfatase activity. Steroids, 64: 825-833. All publications 1999
3689. Ciobanu, L.C., Boivin, R.P., Luu-The, V., Labrie, F., Poirier, D. (1999) Potent inhibition of steroid sulfatase activity by 3-Ο-sulfamate-17alpha-benzyl (or 4'-tert-butylbenzyl)-estra-1,3,5(10)-trienes: combination of two substituents at positions C3 and C17alpha of estradiol. J. Med. Chem., 42: 2280-2286. All publications 1999
416. Couillard, S., Gutman, M., Labrie, F., Candas, B., Labrie, C. (1999) Effect of the combined treatment with the pure antiestrogen EM-800 and radiotherapy on the growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 4857-4863. All publications 1999
806. El-Alfy, M., Luu-The, V., Huang, X.F., Berger, L., Labrie, F., Pelletier, G. (1999) Localization of type 5 17beta-hydroxysteroid dehydrogenase, 3beta-hydroxysteroid dehydrogenase and androgen receptor in the human prostate by in situ hybridization and immunocytochemistry. Endocrinology, 140: 1481-1491. All publications 1999
417. Gutman, M., Couillard, S., Labrie, F., Candas, B., Labrie, C. (1999) Effects of the antiestrogen EM-800 (SCH 57050) and cyclophosphamide alone and in combination on growth of human ZR-75-1 breast cancer xenografts in nude mice. Cancer Res., 59: 5176-5180. All publications 1999
418. Hida, N., Poulin, R., Veilleux, R., Labrie, F. (1999) Differential androgen sensitivity is associated with clonal heterogeneity in steroid metabolism, ornithine decarboxylase regulation and IL-1alpha action in mouse mammary tumor cells. J. Steroid Biochem. Mol. Biol., 71: 71-81. All publications 1999
58. Kelloff, G.J., Lieberman, R., Brawer, M.K., Crawford, E.D., Labrie, F., Miller, G.J. (1999) Strategies for chemoprevention of prostate cancer. Prostate Cancer and Prostatic Diseases, 2: 27-33. All publications 1999
59. Labrie, F. (1999) Combined androgen blockade: its unique efficacy for the treatment of localized prostate cancer, in: De Vita, V.T., Hellman, S. et Rosenberg, S.A., eds: Cancer: Principles and Practice of Oncology, Philadelphia, Lippincott-Raven, pp 1-9. All publications 1999
810. Labrie, F. (1999) Internal symposium: Editorial. Xth International Congress on Hormonal Steroids (Quebec City, Canada 17-21 June 1998). J. Steroid Biochem. Mol. Biol., 69: 1. All publications 1999
3700. Labrie, F. (1999) International Symposium: Journal of Steroid Biochemistry and Molecular Biology Monaco, 25-28 May 1997. Trends Endocrinol. Metab., 10: 1-5. All publications 1999
611. Labrie, F. (1999) Potential of DHEA as hormone replacement therapy, in Reproductive Medicine: Past Present and Future. Proceeding of the 10th World Congress on Human Reproduction, Salvador, Bahia, Brazil, Parthenon Publishing, pp 224-237. All publications 1999
60. Labrie, F. (1999) Prostate cancer: Endocrinology of prostate cancer-intracrinology, in: Pinchera, A., Bertega, X., Binder, C., Fischer, J. et Braverman, L., eds: Textbook of Clinical Endocrinology, Milan, Italy, McGraw-Hill Libri Italia Srl, pp 13-16. All publications 1999
61. Labrie, F., Bélanger, A., Simard, J., Luu-The, V., Labrie, C., Lin, S.-X., Candas, B., Cusan, L. (1999) Impact de l'intracrinologie dans la thérapeutique et la prévention des cancers du sein et de la prostate et de la ménopause, in: Guérité, N. et Leclère, J., eds: Mises au point cliniques d'endocrinologie, nutrition et métabolisme 1999, Paris, France, Les Éditions de Médecine Pratique, pp 169-204. All publications 1999
612. Labrie, F., Bélanger, A., Luu-The, V., Labrie, C., Simard, J., Lin, S.-X. (1999) DHEA, the precursor of androgens and estrogens in peripheral tissues in the human: intracrinology, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, New York, Walter de Gruyter, pp 299-342. All publications 1999
613. Labrie, F., Bélanger, A., Luu-The, V., Simard, J., Lin, S.-X., Cusan, L., Labrie, C. (1999) Role of DHEA transformation into androgens and estrogens in peripheral intracrine tissues, in: Thijssen, J.H.H. et Nieuwenhuyse, H., eds: DHEA a comprehensive review (Proceedings Workshop, Amsterdam 1997), New York, Parthenon Publishing, pp 69-103. All publications 1999
62. Labrie, F., Candas, B. (1999) Bicalutamide versus Flutamide in combination therapy [Letter to the Editor re: Schellhammer et al. 50: 330-336, 1997]. Urology, 53: 662-663. All publications 1999
63. Labrie, F., Candas, B. (1999) The Quebec study shows a 69% decrease in prostate cancer death [Authors' Response to comment of Alexander and Prescott on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 137. All publications 1999
64. Labrie, F., Candas, B. (1999) Various statistical analyses indicate a marked reduction of prostate cancer death in the Quebec trial [Authors' Response to comment of Boer and Schroder on Prostate 38 (2): 83-91, 1999]. Prostate, 40: 132-134. All publications 1999
65. Labrie, F., Candas, B., Dupont, A., Cusan, L., Gomez, J.L., Suburu, R.E., Diamond, P., Lévesque, J., Bélanger, A. (1999) Screening decreases prostate cancer death: first analysis of the 1988 Quebec prospective randomized controlled trial. Prostate, 38: 83-91. All publications 1999
66. Labrie, F., Cusan, J., Gomez, J., Levesque, J., Candas, B. (1999) Screening and treatment of localized prostate cancer decreases mortality: first analysis of the first prospective and randomized study on prostate cancer screening. Society of the Study of the Aging Male, 2: 33-43. All publications 1999
67. Labrie, F., Cusan, L., Gomez, J.-L., Bélanger, A., Candas, B. (1999) Long-term combined androgen blockade alone for localized prostate cancer. Mol. Urol., 3: 217-226. All publications 1999
420. Labrie, F., Labrie, C., Bélanger, A., Simard, J., Gauthier, S., Luu-The, V., Mérand, Y., Giguère, V., Candas, B., Luo, S., Martel, C., Singh, S.M., Fournier, M., Coquet, A., Richard, V., Charbonneau, R., Charpenet, G., Tremblay, A., Tremblay, G., Cusan, L., Veilleux, R. (1999) EM-652 (SCH 57068), a third generation SERM acting as pure antiestrogen in the mammary gland and endometrium. J. Steroid Biochem. Mol. Biol., 69: 51-84. All publications 1999
68. Labrie, F., Simard, J., Coquet, A., Leblanc, G., Candas, B. (1999) Relative potency of bicalutamide (Casodex) and Flutamide (Eulexin) [Letter to the Editor: Reply by the authors re: 50: 913-919, 1997]. Urology, 54: 195-197. All publications 1999
821. Labrie, F., Simard, J., Pasqualini, J.R. (1999) Potential of DHEA as hormonal replacement therapy, 486 pages. All publications 1999
421. Labrie, F.; (1999). EM-652: a pure anti-estrogen discovered and developed in Canada. The best hope for breast cancer prevention and treatment. Can. Breast Cancer Network, 4: Vol. 4, p. 7. All publications 1999
422. Pelletier, G., Luu-The, V., Charbonneau, A., Labrie, F. (1999) Cellular localization of estrogen receptor beta messenger ribonucleic acid in cynomolgus monkey reproductive organs. Biol. Reprod., 61: 1249-1255. All publications 1999
4726. Pelletier, G., Luu-The, V., Tetu, B., Labrie, F. (1999) Immunocytochemical localization of type 5 17beta-hydroxysteroid dehydrogenase in human reproductive tissues. J. Histochem Cytochem., 47: 731-738. All publications 1999
615. Tchernof, A., Labrie, F., Després, J.P. (1999) DHEA, obesity and cardiovascular disease, in: Kalimi, M. et Regelson, W., eds: Dehydroepiandrosterone (DHEA) Biochemical, Physiological and Clinical Aspects, Berlin, Walter de Gruyter, pp 191-213. All publications 1999
<< previous | 2 | 3 | 4 | 5 | 6 | 7 | 8 | 9 | 10 next >>

Biography  |  Publications  |  Scientific Conferences  |  Selected Slide Presentations  |  Awards